DrugPatentWatch Database Preview
Drugs in Development Information for GWP42003-P
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for GWP42003-P?
GWP42003-P is an investigational drug.
There have been 23 clinical trials for GWP42003-P.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 9th 2019.
The most common disease conditions in clinical trials are Syndrome, Seizures, and Lennox Gastaut Syndrome. The leading clinical trial sponsors are GW Research Ltd, University of Utah, and University of Colorado, Denver.
There are seven hundred and forty-three US patents protecting this investigational drug and three international patents.
Summary for GWP42003-P
| US Patents | 743 |
| International Patents | 3,969 |
| US Patent Applications | 1,923 |
| WIPO Patent Applications | 1,233 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2019-12-09) |
| Vendors | 21 |
Recent Clinical Trials for GWP42003-P
| Title | Sponsor | Phase |
|---|---|---|
| Investigation of Cognitive Outcomes With Cannabidiol Oral Solution | GW Research Ltd | Phase 4 |
| Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | GW Research Ltd | Phase 3 |
| An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | GW Research Ltd | Phase 2 |
Clinical Trial Summary for GWP42003-P
Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P
US Patents for GWP42003-P
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GWP42003-P | Start Trial | Pharmaceutical formulations | GW Pharma Limited (Cambridge, GB) | Start Trial |
| GWP42003-P | Start Trial | Compositions and methods for treating chronic inflammation and inflammatory diseases | Infirst Healthcare Limited (London, GB) | Start Trial |
| GWP42003-P | Start Trial | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (Huntington, NY) | Start Trial |
| GWP42003-P | Start Trial | METAP2 inhibitors and methods of treating obesity | SynDevRx, Inc. (Cambridge, MA) | Start Trial |
| GWP42003-P | Start Trial | Compositions, uses and methods for making them | Start Trial | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GWP42003-P
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GWP42003-P | Australia | 2002231970 | 2021-02-14 | Start Trial |
| GWP42003-P | Canada | 2438097 | 2021-02-14 | Start Trial |
| GWP42003-P | Canada | 2533400 | 2021-02-14 | Start Trial |
| GWP42003-P | China | 1886117 | 2021-02-14 | Start Trial |
| GWP42003-P | Cyprus | 1115072 | 2021-02-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
